GlassScriptPhysician profile
Kurt H Bowman
NPI 1578727343
$13,253.94
in general payments reported to CMS, 2019-2025
40 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,280 · 2020: $910 · 2021: $1,293 · 2022: $2,734 · 2023: $5,492 · 2024: $286 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905 · Consulting Fee: $2,165 · Travel and Lodging: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.87 |
| Consulting Fee | $2,165.00 |
| Travel and Lodging | $965.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,124.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,933.71 | 2019-2023 | Fasenra, Breztri, Tagrisso |
| Glaxosmithkline, LLC. | $1,564.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $968.41 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $510.40 | 2021-2023 | Acthar |
| Grifols USA, LLC | $497.07 | 2019-2023 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $428.35 | 2019-2023 | Dupixent |
| Jazz Pharmaceuticals INC. | $384.74 | 2019-2024 | |
| Philips North America LLC | $211.45 | 2019-2023 | |
| Biomerieux INC | $208.61 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $198.66 | 2019-2022 | |
| Pulmonx Corporation | $168.45 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Inari Medical, INC. | $156.08 | 2022 | |
| Amgen INC. | $154.57 | 2021-2023 | Tezspire |
| Insmed, INC. | $142.06 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.